Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$27.51 USD
-0.55 (-1.96%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $27.51 0.00 (0.00%) 7:22 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Earnings News For APLS
-
Apellis (APLS) Q2 Earnings Beat, Syfovre Sales Drive Revenues
-
Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Tops Revenue Estimates
-
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
-
Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Why Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
-
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
-
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
-
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
-
Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know
-
Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound?
-
Apellis (APLS) Q4 Earnings Miss, Revenues Meet Estimates
-
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Lags Revenue Estimates
-
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
-
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
-
Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue?
-
Apellis (APLS) Q3 Loss Wider Than Expected, Syfovre Drives Sales
-
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates
-
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
-
Apellis Pharmaceuticals, Inc. (APLS) Up 67.8% Since Last Earnings Report: Can It Continue?
-
Apellis (APLS) Q2 Earnings Top, Syfovre Sales Boost Revenues
-
Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Tops Revenue Estimates
-
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
-
Apellis (APLS) Q1 Earnings Miss, Empaveli & Syfovre Fuel Growth
-
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
-
Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results